NCT06375304View on ClinicalTrials.gov

The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

May 1, 2027

Conditions
HIV Infections
Interventions
DRUG

B/F/TAF

"The intervention consists of prescribing B/F/TAF to eligible ART-experienced migrant patients, free of charge, in four care settings, for 12 months (48 weeks).~B/F/TAF is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements."

Trial Locations (1)

H4A3T2

Research Institute of the McGill University Health Centre, Montreal

All Listed Sponsors
lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT06375304 - The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study | Biotech Hunter | Biotech Hunter